Showing 5451-5460 of 8729 results for "".
- In With the Old: Curettage and Cryosurgery Still Effective for BCChttps://practicaldermatology.com/news/in-with-the-old-curettage-and-cryosurgery-still-effective-for-bcc/2461815/The combination of curettage and cryosurgery is a safe and effective treatment method for basal cell carcinoma, and now, a new study presents the results from testing different variants of the method. The current study, which appears in the Journal of the American Academy of Dermat
- Bimekizumab Update: FDA Still Reviewing UCB's BLAhttps://practicaldermatology.com/news/bimekizumab-update-fda-still-reviewing-ucbs-bla/2461813/The U.S. Food & Drug Administration (FDA) is still reviewing UCB’s Biologics License Application (BLA) for bimekizumab for moderate to severe plaque psoriasis, UCB reports. UCB previously
- CHMP Recommends Approval of Leo's Adtralza Pre-filled 2 mL Penhttps://practicaldermatology.com/news/chmp-recommends-approval-of-leos-adtralza-pre-filled-2-ml-pen-5/2461812/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending the approval of Adtralza (tralokinumab) in a (300 mg) 2 mL pre-filled pen. With the pre-filled syringe, a single 300-mg dose given every other week rathe
- DataDerm in Action: AAD Launches Project to Improve Outcomes for GPP Patientshttps://practicaldermatology.com/news/aad-launches-project-to-improve-outcomes-for-gpp-patients/2461804/The American Academy of Dermatology is launching a new project to develop educational resources to improve the evaluation, diagnosis, and treatment of patients with generalized pustular psoriasis (GPP). The AAD is working with Boehringer Ingelheim and using OM1’s data aggregation
- Paradigm Shift: Can Harnessing the Power of Healthy Cells Prevent Skin Cancer?https://practicaldermatology.com/news/paradigm-switch-can-harnessing-the-power-of-healthy-cells-prevent-skin-cancer/2461803/Do simple wounds or surgery increase skin cancer risks by expanding mutated cells? No, according to a new study by researchers at Yale and the Karolinska Institute in Sweden. Rather than promoting mutant cell growth, injury promotes healthy-cell expansion which keeps mutated cell growth
- Osteopontin Potently Stimulates Hair Follicle Stem Cells for Robust Hair Growthhttps://practicaldermatology.com/news/osteopontin-potently-stimulates-hair-follicle-stem-cells-for-robust-hair-growth/2461802/Do hairy moles hold the secret to understanding hair growth? Maybe, according to research published in the June 21, 2023 issue of Nature. Using a mouse model, researchers tracked the activity of ha
- The Canadian Dermatology Association Announces 2023 Award Recipientshttps://practicaldermatology.com/news/the-canadian-dermatology-association-announces-2023-award-recipients/2461800/The Canadian Dermatology Association’s (CDA) 2023 Lifetime Achievement Award goes to Drs. James D. Walker and Peter Hull. Dr. Walker developed and constructed the first Mohs Surgical Unit to treat skin cancer at The Ottawa Hospital (TOH). He also helped raise more than $
- Proof of Concept: Oral Orismilast Reduces Pain, Improves Q of L in HShttps://practicaldermatology.com/news/proof-of-concept-oral-orismilast-reduces-pain-improves-q-of-l-in-hs/2461799/Oral orismilast is showing promise in adult with hidradenitis suppurativa (HS), according to positive topline results from the OSIRIS investigator-initiated proof-of-concept study. UNION therapeutics’ Orismilast is a high potency, next-generation PDE4
- Deloitte Launches 'Illustrate Change' Medical Illustration Libraryhttps://practicaldermatology.com/news/deloitte-launches-illustrate-change-medical-illustration-library/2461794/Deloitte is launching "Illustrate Change," a project that seeks to increase representation in medical i
- Health Canada Greenlights Sun Pharma’s Winlevi for Acnehttps://practicaldermatology.com/news/health-canada-greenlights-sun-pharmas-winlevi-for-acne/2461792/Health Canada has given its nod to Sun Pharma’s Winlevi (clascoterone cream 1%). Winlevi an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. It will be available in Canada this Fall. "